Obesity is a major challenge for the prevention of metabolic diseases and complications associated with the disease. In recent years, there are increasing interests in the treatment of obesity by targeting GLP-1 signaling (DeFronzo et al., 2005; Astrup et al., 2009; Shah and Vella, 2014; Ladenheim, 2015; Isaacs et al., 2016). Notably, liraglutide, a GLP-1 analog, has become the first GLP-1 receptor targeting agent proved by FDA for management of obesity recently (Rajeev and Wilding, 2016). Clinical studies showed that this daily injecting agent is effective in reducing body weight of obese patients with or without T2D. The SCALE study involved 3731 patients without T2D showed that liraglutide at a once-daily dose of 3.0 mg, when used as an adjunct to a reduced-calorie diet and increased physical activity, increased weight loss in patients with a BMI of more than 30 or more than 27 if they had hypertension and dyslipidemia. The mean change in body weight with liraglutide was −8.0 ± 6.7% (−8.4 ± 7.3 kg) which was generally maintained over the course of the 56-week main study period, as long as the patients continued treatment (Pi-Sunyer et al., 2015). The LEAD1-6 series of trials showed that a once-daily dose of 1.2–1.8 mg of liraglutide yielded reductions of body weight by 2–3 kg in T2D (Rajeev and Wilding, 2016). Other GLP-1 analogs have also been found to be effective in treating obesity (Woodward and Anderson, 2014; Thompson and Trujillo, 2015). Specifically, the once a week dosing dulaglutide has demonstrated glycemic lowering effects and weight reduction similar to liraglutide and exenatide. Importantly, this once-weekly agent has demonstrated superior therapeutic effects when used as monotherapy compared with the twice-daily exenatide (Thompson and Trujillo, 2015). These finding highlighted that a strategy targeting GLP-1 signaling is clinically effective in treating obesity.